Lumexa Imaging (LMRI) logo

Lumexa Imaging's IPO

Lumexa Imaging · Filed Nov 17 · Nasdaq · Form S-1

Listed Dec 11, 2025 at $18.50 on Nasdaq as LMRI. Today 25% below its $18.50 offer price; its first day closed +0.1%.

Offer price: $18.50, a share
Market cap: $1.75B, from its filing
Shares: 25,000,000, offered

From its final prospectus (424B4) on SEC EDGAR.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

See LMRI ranked, liveSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

What does Lumexa Imaging do?

Lumexa Imaging's facts, each with its source
FactLumexa
Imaging
What it does“We are one of the largest national providers of diagnostic imaging services.”From its final prospectus (424B4) of Dec 12, 2025
Founded2018From its final prospectus (424B4) of Dec 12, 2025
HeadquartersRaleigh, North CarolinaFrom its final prospectus (424B4) of Dec 12, 2025
Websitelumexaimaging.comFrom its final prospectus (424B4) of Dec 12, 2025

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

Lumexa Imaging's facts, each with its source
FactLumexa
Imaging
Shares offered25,000,000From the final prospectus (424B4) filed Dec 12, 2025
Offer price$18.50 a shareFrom the final prospectus (424B4) filed Dec 12, 2025
Underwriters' option3,750,000 more sharesFrom the final prospectus (424B4) filed Dec 12, 2025
UnderwritersBarclays, J.P. Morgan, Jefferies, Deutsche Bank, Wells Fargo, and Leerink Partners, with 9 moreFrom the final prospectus (424B4) filed Dec 12, 2025, as its cover names them
ExchangeNasdaq Global Select Market, as LMRIFrom the final prospectus (424B4) filed Dec 12, 2025
Shares outstanding after94,565,652From the final prospectus (424B4) filed Dec 12, 2025
Market cap at the offer price$1.75 billionBreakaway's arithmetic from the prospectus's share count

What risks does Lumexa Imaging name first?

  1. “Our ability to generate revenue depends in large part on referrals from physicians and other healthcare providers.”
  2. “Because many of our costs are fixed, lower scan volumes or other decreases to revenues could adversely affect the profitability of our business.”
  3. “Our ability to maintain and attract new business depends upon the quality of our services, our reputation and the professional reputations of our radiologists, joint venture partners and the third-party providers with whom we contract.”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Dates so far

Lumexa Imaging's IPO dates, each with its source
WhatDay
Registration filedForm S-1, SEC EDGARNov 17, 2025
Declared effective by the SECSEC notice of effectiveness, SEC EDGARDec 10, 2025
Pricedfinal prospectus (424B4), filed Dec 12, SEC EDGARDec 10, 2025
Exchange registration filedexchange registration (Form 8-A), SEC EDGARDec 11, 2025
First tradeMassive's IPO calendarDec 11, 2025
Lock-up endsfinal prospectus, SEC EDGAR: “180 days after the date of this prospectus”Jun 8, 2026

How did its first days trade?

From its daily bars, each close against its $18.50 offer price.

Lumexa Imaging's first sessions
DayOpenCloseFrom the
offer
Dec 11$18.65$18.52+0.1%
Dec 12$18.30$18.53+0.2%
Dec 15$18.78$18.52+0.1%
Dec 16$18.50$17.90-3.2%
Dec 17$17.75$17.08-7.7%

What is Lumexa Imaging's Quality Score?

4

Below Average

230 trading days so far.

LMRI's page, with every reason behind its score

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

The other IPOs expected

The other IPOs expected or in registration
CompanyPrice

Lumexa Imaging IPO questions

When is Lumexa Imaging's IPO?

Listed Dec 11, 2025 at $18.50 on Nasdaq as LMRI.

What is Lumexa Imaging's IPO price?

Lumexa Imaging's IPO priced at $18.50 a share, per its final prospectus of Dec 12, 2025.

How many shares is Lumexa Imaging selling?

25,000,000 shares, and the underwriters may buy 3,750,000 more, per its final prospectus (424B4).

Who are the underwriters?

Barclays, J.P. Morgan, Jefferies, Deutsche Bank, Wells Fargo, Leerink Partners, William Blair, Capital One Securities, Fifth Third, Raymond James, PNC Capital Markets, Academy Securities, Loop Capital Markets, R. Seelaus, and Co., as the prospectus's cover names them.

When does the lock-up end?

Lumexa Imaging's IPO lock-⁠up ends Jun 8, 2026. Its final prospectus says: “180 days after the date of this prospectus.”

Does Breakaway rate Lumexa Imaging?

Lumexa Imaging has a Quality Score of 4 today. The score counts the 14 chart checks and the company's filings; a check that needs more history than a new stock has waits for it.

Can Breakaway say where Lumexa Imaging's price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from: how the IPO pages are made.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live.

Each stock that listed in the last 90 days, with its Quality Score from its second day of trading, its insider filings, and its lock-up date, and an optional alert the day a company you follow lists.

See all 10 new listings ranked

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Sources: Lumexa Imaging Holdings, Inc.'s final prospectus (424B4) of Dec 12, 2025; the prices, the stock's daily bars, 15 minutes behind.

Not advice. Figures from each company's SEC filings, linked on each line. Breakaway is not an underwriter, broker, or adviser, and does not say where a price will go.

Scores as of 11:07 PM ET, 15 minutes behind.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.